The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, researchers uncovered clues explaining risks of heart disease, lung disease, Covid-19 and… Read More
The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, results showed the new Wegovy pill could help patients lose 17% of… Read More
News round-up for 15 June – 19 June by Bruno Quinney, Content Team at DDW. This week, results show the new Wegovy pill could help patients lose 17% of their body weight. Elsewhere, advances have been made in both cancer treatment and cancer research. The top stories: … Read More
Results presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting from the Phase III FIGHT-302 trial showed that Incyte’s pemigatinib (Pemazyre), significantly improved progression-free survival in the first-line setting in cholangiocarcinoma (bile duct cancer). The drug was compared with gemcitabine and cisplatin, a long-standing… Read More
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. In the same week DDW shared expert insights from the 2025 ASCO annual meeting, there… Read More
News round-up for 16-20 June by DDW Senior Digital Content Editor Diana Spencer. In the same week DDW shared expert insights from the 2025 ASCO annual meeting, there have been several significant developments in oncology drug discovery, including new therapy options for some difficult to treat cancers. Read More
This year’s American Society of Clinical Oncology (ASCO) Annual Meeting took place at the McCormick Place Convention Center in Chicago from 30 May to 3 June 2025. DDW’s Megan Thomas collected commentary from industry experts in attendance. CCR8 therapies gain clinical significance Stephan Schann is Chief Scientific Officer at Domain… Read More
Perspective Therapeutics has shared interim results from its ongoing Phase I/IIa clinical trial of [212Pb]VMT-α-NET at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The Phase I/IIa clinical trial is a multi-centre open-label dose escalation and dose expansion study of [212Pb]VMT-α-NET in patients with unresectable… Read More
Results of a global study presented at the American Society of Clinical Oncology (ASCO) annual meeting have shown that camizestrant for advanced breast cancer can be used to treat emerging tumours. The study was funded by AstraZeneca and co-led by researchers at The Institute of Cancer Research,… Read More
Biotech venture creation studio RBL has launched Sentinel BioTherapeutics, a spin-out from Rice University, at the 2025 ASCO Annual Meeting. This is RBL’s first company spin-out since its formation in October 2024 and positions Sentinel to begin preparations ahead of the next phase of clinical development for… Read More
A multispecific antibody candidate for B cell lymphoma preferentially engaged CD47 in presence of co-engagement of CD20 and CD19, in preclinical investigations. One dose of Nutcracker Therapeutics’ NTX-472 in vivo rapidly depleted B cells with no detectable binding to red blood cells. The results… Read More
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. With the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting concluding this week,… Read More
News round-up for 3-7 June by DDW Senior Digital Content Editor Diana Spencer. With the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting concluding this week, the headline news has all focused on breakthrough cancer research shared at the event. The top stories:… Read More
With the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from 30 May to 3 June, the drug discovery announcements have been coming thick and fast, with many new cancer therapies making significant strides forward in our ability to treat the disease. Lorbrena advances… Read More
Patients taking semaglutide (the active ingredient in Wegovy and Ozempic) were 19% less likely to develop 13 obesity-related cancers, according to new data presented at ASCO 2024. The research, led by the Case Western Reserve University in Ohio and reported in The Guardian, also found… Read More
Cancer vaccine mRNA-4157 (V940) in combination with Keytruda reduced the risk of recurrence or death by 49% in patients with resected high-risk melanoma, according to follow-up data presented at ASCO 2024. The combination therapy was also shown to reduce the risk of distant metastasis or… Read More
